En Es
Categories

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological functions. The company also provides sequencing and array-based solutions for genetic analysis, as well as genotyping, NIPT and whole-genome sequencing services for government laboratories, hospitals, an ...
Products Covid-19NewsSummary
Close

Covid-19 Illumina

Clinical Laboratory

SARS-CoV-2 NGS Test
Illumina COVIDSeq Test

The Illumina COVIDSeq Test is a high-throughput, next-generation sequencing test is intended for the detection of SARS-CoV-2 virus RNA in authorized countries and virus genome analysis for research use. This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19.
More details

SARS-CoV-2 (COVID-19) Test
Illumina COVIDSeq Test

The Illumina COVIDSeq Test is the first NGS test approved for use under the US Food and Drug Administration’s Emergency Use Authorization (EUA). This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19. The test can be run on the Illumina NovaSeq 6000 Sequencing System, NextSeq 500 Sequencing System, NextSeq 550 Sequencing System, or NextSeq 550Dx Instrument.
More details
Close

News of Illumina

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

20 Aug 2021
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
Illumina, Inc. (San Diego, CA, USA) has acquired GRAIL (Menlo Park, CA, USA), a healthcare company focused on life-saving early detection of multiple cancers.
Read More
Close

About Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological functions. The company also provides sequencing and array-based solutions for genetic analysis, as well as genotyping, NIPT and whole-genome sequencing services for government laboratories, hospitals, and reference laboratories, among others.
FaceBook Twitter Google+ Linked in
SARS-CoV-2 NGS Test

SARS-CoV-2 NGS Test

Model: Illumina COVIDSeq Test
Request Information

Description:

The Illumina COVIDSeq Test is a high-throughput, next-generation sequencing test is intended for the detection of SARS-CoV-2 virus RNA in authorized countries and virus genome analysis for research use. This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19.

Features Specifications

Features

• Accurate: Detects 98 targets on SARS-CoV-2 for highly accurate detection
• Comprehensive: Detects SARS-CoV-2 virus RNA; reports consensus genome calling for virus analysis under research use
• Quality Controlled: Built in quality control features in every reaction
• Flexible: Seamless end-to-end workflow. Temperature specification allows use of different thermocyclers.
• Scalable: Available on NovaSeq 6000, NextSeq 2000, or NextSeq 500/550/550Dx (in RUO mode) systems. Request Information

Specifications

• Species Details: Detects SARS-CoV2 viral RNA in human nasopharyngeal, oropharyngeal, and mid-turbinate nasal swab samples
• System Compatibility: NextSeq 2000, NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode, NovaSeq 6000
• Technology: Sequencing
• Method: Amplicon Sequencing, Targeted RNA Sequencing
• Species Category: Virus, Human
• Nucleic Acid Type: RNA Request Information

Send A Message To This Supplier

* Required Information
* Email
To
Illumina (SARS-CoV-2 NGS Test)
* Message

Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions